Cargando…

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS

Detalles Bibliográficos
Autores principales:	Rosenthal, Allison, Jun, Monika, Munoz, Javier, Wang, Tongsheng, Mutebi, Alex, Wang, Anthony, Yang, Shibing, Osei-Bonsu, Kojo, Elliott, Brian, Kalsekar, Anupama, Rivas Navarro, Fernando, Ip, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430911/ http://dx.doi.org/10.1097/01.HS9.0000971492.92995.27

Ejemplares similares

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
por: Ip, Andrew, et al.
Publicado: (2023)

Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
por: Lu, D, et al.
Publicado: (2017)

Gastrotomy with Removal of 1149 Foreign Bodies
Publicado: (1913)

P1176: CLINICAL OUTCOMES OF NOVEL THERAPIES IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
por: Crombie, Jennifer, et al.
Publicado: (2023)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

The use of tafasitamab in diffuse large B-cell lymphoma
por: Düll, Johannes, et al.
Publicado: (2021)

Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma
por: Patra-Kneuer, Maria, et al.
Publicado: (2023)

Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Polatuzumab vedotin for B-cell lymphoma
Publicado: (2020)

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis
por: Bonafede, Machaon M, et al.
Publicado: (2011)

Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
por: Li, Tommy, et al.
Publicado: (2022)

Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
por: Nowakowski, Grzegorz S., et al.
Publicado: (2023)

1149. Reducing Piperacillin/Tazobactam Use in Children with Acute Perforated Appendicitis
por: Seddik, Talal B, et al.
Publicado: (2019)

Epidemiological and clinical features of 1,149 persons with Lyme disease identified by laboratory-based surveillance in Connecticut.
por: Petersen, L. R., et al.
Publicado: (1989)

Correction to: Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Excellent Interim Treatment Response with Polatuzumab Vedotin
por: Mehtap, Özgür, et al.
Publicado: (2020)

Development of an evidence-based regimen of prednisolone to treat giant cell arteritis – the Norwich regimen
por: Mukhtyar, Chetan, et al.
Publicado: (2019)

Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen
Publicado: (1989)

Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
por: Salles, Gilles, et al.
Publicado: (2021)

Preclinical study of CD19 detection methods post tafasitamab treatment
por: Ilieva, Kristina, et al.
Publicado: (2023)

Regimen
Publicado: (1856)

Regimen
Publicado: (1868)

Regimen
Publicado: (1860)

Regimen
Publicado: (1882)

Regimen
Publicado: (1881)

Regimen
Publicado: (1878)

A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy
por: Gouni, Sushanth, et al.
Publicado: (2022)

Epcoritamab-bysp (Epkinly) – A phenomenal breakthrough in the treatment of diffuse large B-cell lymphoma
por: Riaz, Rumaisa, et al.
Publicado: (2023)

Comparison of capecitabine-based regimens with platinum-based regimens in Chinese triple-negative breast cancer patients with liver metastasis
por: Chen, Yimeng, et al.
Publicado: (2021)

Effectiveness of vonoprazan-based regimens compared with proton pump inhibitor-based regimens as first-line Helicobacter pylori agents
por: Kakiuchi, Toshihiko
Publicado: (2023)

Transformed Waldenström Macroglobulinemia Responsive to Tafasitamab Plus Lenalidomide: A Case Report
por: Nasir, Syed Alishan, et al.
Publicado: (2022)

Bortezomib-Based Regimens and Plasma Cell Leukemia
por: Bolaman, Ali Zahit
Publicado: (2021)

Cost-Effectiveness of Vonoprazan- and Rifabutin-Based Regimens
por: Almenoff, June
Publicado: (2023)

Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male
por: Adamu, Bappa, et al.
Publicado: (2016)

Efficacy and Tolerability of Tenofovir Disoproxil Fumarate Based Regimen as Compared to Zidovudine Based Regimens: A Systematic Review and Meta-Analysis
por: Dadi, Tegene Legese, et al.
Publicado: (2017)

Regímenes aduaneros /
por: Tamayo Contreras, Porfirio
Publicado: (2020)

Intravascular large B‐cell lymphoma treated with polatuzumab‐based salvage therapy: A rare case
por: Bitar, George, et al.
Publicado: (2021)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Oxaliplatin-Based Regimen is Superior to Cisplatin-Based Regimen in Tumour Remission as First-line Chemotherapy for Advanced Gastric Cancer: A Meta-Analysis
por: Zhang, Fei, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_658no2200jf8qb47es7p0r5579